Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
$0.2303
Day's Change
-0.0319 (-12.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2993
Day's Low
0.2303
Volume
(Heavy Day)
Volume:
1,727,500

10-day average volume:
815,612
1,727,500

Moderna Inc. Stock Falls Tuesday, Underperforms Market

4:32 pm ET July 26, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Moderna Inc. MRNA shed 2.89% to $160.90 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.87% to 11,562.57 and Dow Jones Industrial Average DJIA falling 0.71% to 31,761.54. Moderna Inc. closed $336.59 below its 52-week high ($497.49), which the company reached on August 10th.

The stock underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. ABBV rose 0.43% to $150.87, Amgen Inc. AMGN rose 0.97% to $251.14, and AstraZeneca PLC ADR AZN rose 0.85% to $66.72. Trading volume (2.8 M) remained 2.6 million below its 50-day average volume of 5.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 26, 2022.

	

(END) Dow Jones Newswires

July 26, 2022 16:32 ET (20:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.